EANS-Adhoc: SYGNIS Pharma AG / Genetrix Life Sciences, A.B., and Genetrix, S.L., Granted Exemption from Mandatory Tender Offer to Shareholders of SYGNIS Pharma AG

ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.

24.09.2012

Heidelberg, September 24,2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) was informed that the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht; BaFin) has granted an exemption to Genetrix Life Sciences, A.B., and to its parent company Genetrix, S.L., from the obligation to publish the acquisition of control over SYGNIS Pharma AG, and to provide BaFin an offer document, and to publish a mandatory tender offer, in the event these companies will gain control over SYGNIS Pharma AG subsequently to the resolution regarding the capital increase against contribution in kind to be resolved on the Shareholders' Meeting convened on October 17, 2012, coming in force.

The resolution regarding the contribution in kind by way of contributing the shares of X-Pol Biotech, S.L., into SYGNIS Pharma AG coming in force, Genetrix Life Sciences, A.B., and their parent company Genetrix, S.L., will acquire control over SYGNIS Pharma AG in the meaning of Section29 (2) WpÜG and would have been required to make a mandatory tender offer to the shareholders of SYGNIS Pharma AG had the exemption not been granted.
**** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG

Peter Willinger
Co-CEO/CFO
Tel: +49 6221 454 836
Email: willinger@sygnis.de

### Disclaimer
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

end of announcement euro adhoc

issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share

stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English

Digital press kit: http://www.ots.at/pressemappe/EASY_65063/aom

Rückfragen & Kontakt:

Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | EAE0002